Saturday 17 October 2026 Export WGS’s income statement to Excel — free account

GeneDx Holdings Corp.

GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024. In the quarter to June 2026, revenue grew 11.4%, EPS fell 257.9%, free cash flow fell 585.6% and total debt rose 87.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

63.60 6.62 −9.43%

Follow WGS

Alert me

Market cap: $2.1B
P/E: 0.0×
Fwd P/E: −17.4×
Dividend yield: —
F-score: 6/9
Altman Z: 7.80
Beneish M: −2.36
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 106.60

Total sells 21.30

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	3	1	—	—	—	—
Sell	1	5	2	2	7	2	—	5	—	—	4	—

Insider Ownership 2.73%

Capital & Financial Ratios $m

Market Cap 2,090.00

Revenue 454.43

Net Income (106.36)

Free Cash Flow (75.80)

Net Debt (35.71)

Current Ratio 3.30

Debt/Equity 0.40

P/E ratio 0.00

Fwd P/E (17.40)

P/S ratio 4.16

P/B ratio 7.74

Past 5Y EPS Growth —

This Y EPS Growth (92.86%)

Next Y EPS Growth 1,098.57%

Next Y revenue growth 12.69%

Next 5Y EPS Growth 8.33%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 57.62%

10-year low 10-year high

P/B against its own 10 years 69.76%

10-year low 10-year high

EV/Sales against its own 10 years 50.34%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	130	141	171	133
Receivables	33	38	74	84
Inventory	9	11	14	18
Other	—	—	—	—
	182	198	268	246

	2023	2024	2025	Q'26
Payables	37	31	58	42
ST’ Debt	—	—	—	—
Other	16	20	47	27
	59	55	109	75

Compound Annual Growth %

	10y	5y	3y
Sales	—	18.98%	22.13%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	134.05%	6.70%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	102	114	—	—	—
’25	87	103	117	121	428
’24	62	71	77	96	305
’23	43	49	53	57	203
’22	54	36	83	61	235
’21	64	47	43	58	212
’20	—	—	39	—	179

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(32)	(29)	—	—	—
’25	10	10	16	(3)	33
’24	(16)	(5)	(4)	(3)	(28)
’23	(56)	(54)	(41)	(30)	(180)
’22	(81)	(85)	(88)	(65)	(319)
’21	(42)	(25)	(71)	(52)	(190)
’20	—	—	(75)	74	(93)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(39)	(39)	—	—	—
’25	4	8	10	(7)	14
’24	(17)	(6)	(5)	(6)	(34)
’23	(56)	(53)	(41)	(32)	(182)
’22	(85)	(88)	(93)	(67)	(333)
’21	(47)	(30)	(75)	(60)	(211)
’20	—	—	(95)	95	(125)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.16)	(0.60)	—	—	—
’25	(0.23)	0.36	(0.27)	(0.61)	(0.73)
’24	(0.78)	(1.10)	(0.31)	0.23	(1.94)
’23	(3.04)	(1.84)	(1.64)	(0.92)	(7.23)
’22	(10.23)	(8.25)	(6.60)	(28.14)	(53.79)
’21	(11.51k)	(1.38k)	4.95	(5.61)	(74.92)
’20	—	—	(15.07m)	0.00	(1.59m)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	318.78	140.58	7.26	1.16	2.47	55.17	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	404.25	896.94	154.11	17.92	89.11	170.87
People
People	Employees	—	—	—	—	—	1,200	1,100	1,000	1,000	1,300
	Revenue/emp, $m	—	—	—	0.00	0.00	0.18	0.21	0.20	0.31	0.33
Income, $m
Income, $m	Revenue	—	—	—	196	179	212	235	203	305	428
	Gross margin, %	—	—	—	42.20	2.25	(7.82)	(11.40)	44.43	63.64	69.74
	EBT	—	—	—	(30)	(241)	(245)	(598)	(177)	(53)	(21)
	EBT margin, %	—	—	—	(15.14)	(134.58)	(115.64)	(254.81)	(87.23)	(17.23)	(4.94)
	Net income	—	0	—	(30)	(241)	(245)	(549)	(176)	(52)	(21)
	Depreciation	—	—	—	6	12	22	59	34	22	25
Per share, $
Per share, $	Revenue	—	—	—	0.00	896,610.00	64.80	22.93	8.33	11.36	14.93
	Earnings	—	—	—	(7,905,874.00)	(0.14)	(74.92)	(53.79)	(7.23)	(1.94)	(0.73)
	Cash flow	—	—	—	0.00	(465,640.00)	(58.15)	(31.18)	(7.41)	(1.06)	1.16
	Capex	—	—	—	0.00	(159,870.00)	(6.35)	(1.40)	(0.07)	(0.20)	(0.66)
	Free cash flow	—	—	—	0.00	(625,510.00)	(64.50)	(32.58)	(7.48)	(1.26)	0.50
	Book value	—	—	—	0.00	21,940.00	118.52	24.78	9.38	9.12	10.76
	Shares, m	—	—	—	0	0	3	10	24	27	29
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	0.00	2.27	0.40	0.32	6.77	8.71
	P/B	—	—	—	0.00	47.05	1.24	0.37	0.28	8.43	12.09
	EV/Sales	—	—	—	0.00	0.00	0.44	(0.10)	(0.07)	6.47	8.43
	EV/FCF	—	—	—	0.00	0.00	(0.44)	0.07	0.07	(58.19)	252.56
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(19)	(93)	(190)	(319)	(180)	(28)	33
	Capex	—	—	—	(15)	(32)	(21)	(14)	(2)	(5)	(19)
	Free cash flow	—	—	—	(34)	(125)	(211)	(333)	(182)	(34)	14
Balance, $m
Balance, $m	Working capital	—	—	—	—	101	382	68	124	143	159
	Total debt	—	—	—	—	40	11	6	53	52	48
	Net debt	—	—	—	—	(68)	(390)	(118)	(77)	(89)	(123)
	Shareholders’ equity	—	—	—	—	4	388	254	228	245	308
Returns, %
Returns, %	ROA	—	—	—	0.00	(191.81)	(60.91)	(105.06)	(38.64)	(12.48)	(4.46)
	ROIC	—	—	—	0.00	0.00	0.00	(306.78)	(74.97)	(9.30)	(4.42)
	ROE	—	—	—	0.00	(831.46)	(845.41)	(171.07)	(72.97)	(22.10)	(7.60)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BLLN BillionToOne, Inc.	$4.9B	95.0×	99.4×	+64.40% (above 0%: growing)	n/m	+400.65% (above 0%: growing)	70.45%	5.03%	Compare
ADPT Adaptive Biotechnologies Corporation	$4.1B	— (loss-making)	— (loss-making)	+21.53% (above 0%: growing)	n/m	+42.04% (above 0%: growing)	71.82%	(22.04%)	Compare
VCYT Veracyte, Inc.	$3.6B	29.9×	45.1×	+15.49% (above 0%: growing)	n/m	+32.95% (above 0%: growing)	72.21%	15.29%	Compare
CDNA CareDx, Inc.	$3.5B	29.7×	2,967×	+52.23% (above 0%: growing)	n/m	+223.42% (above 0%: growing)	73.50%	85.81%	Compare
NEO NeoGenomics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+11.21% (above 0%: growing)	n/m	−16.18% (below 0%: shrinking)	45.56%	(4.85%)	Compare
WGS GeneDx Holdings Corp.	$2.1B	— (loss-making)	— (loss-making)	+11.44% (above 0%: growing)	n/m	−585.59% (below 0%: shrinking)	68.37%	(15.25%)
PSNL Personalis, Inc.	$1.7B	— (loss-making)	— (loss-making)	+29.96% (above 0%: growing)	n/m	−123.46% (below 0%: shrinking)	21.21%	(150.25%)	Compare
OPK OPKO Health, Inc.	$1.2B	— (loss-making)	— (loss-making)	+4.32% (above 0%: growing)	n/m	+46.46% (above 0%: growing)	48.92%	(4.26%)	Compare
CSTL Castle Biosciences, Inc.	$1.0B	— (loss-making)	— (loss-making)	+20.14% (above 0%: growing)	n/m	−43.33% (below 0%: shrinking)	77.11%	(2.96%)	Compare
Median of peers	$2.8B	29.9×	99.4×	+20.83%	—	+37.50%	71.13%	(3.61%)

All 52 Diagnostics & Research stocks →

GeneDx Holdings Corp. (WGS) key facts

Strength: GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
GeneDx Holdings Corp. (WGS) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, WGS traded at $63.60, a market capitalization of $2.1 billion.
Return on equity was −7.60% and debt-to-equity 0.40.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 7.80 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.